Trials / Terminated
TerminatedNCT00067041
Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft
A Randomized Placebo-Controlled, 12-Week Multicenter Study of the Safety and Efficacy of Remodulin in Patients With Critical Limb Ischemia Following an Autogenous Vein Infrainguinal Bypass Graft
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- United Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Approximately 30 patients will be enrolled in this 12-week study designed to assess the effect of continuous subcutaneous Remodulin therapy on the outcome of infrainguinal bypass grafts in patients with critical limb ischemia (CLI). Portions of the study will be conducted in the hospital and on an out-patient basis. The study will be conducted at multiple centers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Remodulin (treprostinil sodium) Injection |
Timeline
- Start date
- 2003-03-01
- Primary completion
- 2003-12-01
- Completion
- 2003-12-01
- First posted
- 2003-08-13
- Last updated
- 2013-03-07
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00067041. Inclusion in this directory is not an endorsement.